Cyclophosphamide versus Placebo in Scleroderma Lung Disease-Reference-Cited by-同舟云学术

Cyclophosphamide versus Placebo in Scleroderma Lung Disease

Published:2006-06-22 Issue:25 Volume:354 Page:2655-2666
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Tashkin Donald P.,Elashoff Robert,Clements Philip J.,Goldin Jonathan,Roth Michael D.,Furst Daniel E.,Arriola Edgar,Silver Richard,Strange Charlie,Bolster Marcy,Seibold James R.,Riley David J.,Hsu Vivien M.,Varga John,Schraufnagel Dean E.,Theodore Arthur,Simms Robert,Wise Robert,Wigley Fredrick,White Barbara,Steen Virginia,Read Charles,Mayes Maureen,Parsley Ed,Mubarak Kamal,Connolly M. Kari,Golden Jeffrey,Olman Mitchell,Fessler Barri,Rothfield Naomi,Metersky Mark

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa055120

Cited by 1415 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the mechanism of luteolin improving immune and inflammatory responses in systemic sclerosis based on systems biology and cell experiments;International Immunopharmacology;2024-09

2. Unraveling the role of MiR‐181 in skin fibrosis pathogenesis by targeting NUDT21;The FASEB Journal;2024-09

3. Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results;Current Opinion in Rheumatology;2024-08-28

4. Tuberculosis is the predominant infection in systemic sclerosis: thirty-year retrospective study of serious infections from a single centre;Rheumatology International;2024-08-24

5. Lung Involvement in Systemic Sclerosis—From Pathogenesis to Prediction;Sclerosis;2024-08-17